10.1007/s11883-017-0678-6 [DOI] [PubMed] [Google Scholar] 145.Yang X, Li Y, Li Y, Ren X, Zhang X, Hu D, et al
Clinical responses and synovial vascularity in obese rheumatoid arthritis patients treated with adalimumab and methotrexate
Now their stomachs are paralyzed July 25, 2023 Facial lipoatrophy with semaglutide-related weight loss February 10, 2023 --------------------------------------- Glucagon-like peptide 1 (GLP-1) agonists are medications approved for treatment of diabetes that recently have also been used off label for weight loss.1 Studies have found increased risks of gastrointestinal adverse events (biliary disease,2 pancreatitis,3 bowel obstruction,4 and gastroparesis5) in patients with diabetes.2-5 Because such patients have higher baseline risk for gastrointestinal adverse events, risk in patients taking these drugs for other indications may differ
Theranostics 10(11):51075119 Cheng ZJ, Miao DL, Su QY et al (2019) THZ1 suppresses human non-small-cell lung cancer cells in vitro through interference with cancer metabolism
46 Chaves-FilhoA.EyresC.BlbaumL.LandwehrA.TremblayM
Glucose feeds the TCA cycle via circulating lactate